Management of DAAs Failure

More documents

Recommendations

Info

A- Retreatment <strong>of</strong> patients with previous SOF/DAC failure 1- Non cirrhotics and compensated cirrhotic patients: • Option I: SOF/Qurevo/RBV for 12 weeks. • Option II : SOF/SIM/DAC/RBV for 12 weeks • RBV ineligible: extend therapy for 24 weeks
A- Retreatment <strong>of</strong> patients with previous SOF/DAC failure 1- Non cirrhotics and compensated cirrhotic patients: • Option I: SOF/Qurevo/RBV for 12 weeks. • Option II : SOF/SIM/DAC/RBV for 12 weeks • RBV ineligible: extend therapy for 24 weeks
Page 2 and 3: Management of DAAs Failure Prof. Ga
Page 4 and 5: • HCV is an enveloped, positive-s
Page 6 and 7: Antiviral Resistance • Each patie
Page 8 and 9: All DAAs Can Select Resistant Varia
Page 10 and 11: Barrier to Resistance Low-barrier d
Page 13: NS5B RAV(S) • Sofosbuvir has a hi
Page 16 and 17: Protease inhibitor-Resistant Viruse
Page 18 and 19: SVR12 (%) 24 Wks of LDV/SOF Retreat
Page 20 and 21: DAA Treatment Failure •Relapse or
Page 22 and 23: Treatment recommendations for retre
Page 26 and 27: A- Retreatment of patients with pre
Page 28 and 29: Abstract ID: 849 Author: Ng T. et a
Page 30 and 31: Summary • Treatment-emergent RAV(

Management of DAAs Failure

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?